Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,196 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Complement Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Mountain View, California • Oak Forest, Illinois • Springfield, Illinois + 7 more

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide; Drug · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 311
States / cities: Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more

Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions: Asundexian (BAY2433334), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12,327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 108
States / cities: Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions: Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 919 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 120
States / cities: Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 127
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more

Conditions: Coronary Heart Disease
Interventions: SMT-enhanced Cardiac Rehabilitation, Standard Cardiac Rehabilitation; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 35 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Prostate Cancer
Interventions: Standard of Care; Other
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 21 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 48
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more

Conditions: Congestive Heart Failure
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 161
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more

Conditions: Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions: Armodafinil 100 to 250 mg/day; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more

Conditions: Breast Cancer
Interventions: bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 522
States / cities: Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 84
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 54
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more

Conditions: Atrial Septal Defect Secundum
Interventions: atrial septal occluder; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 65
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 50 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Lp(a) Screening; Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 113
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more

Conditions: Intracranial Arteriosclerosis, Stroke
Interventions: Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 114
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more

Conditions: Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
Interventions: Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis; Drug · Procedure · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 161
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 858
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more

Conditions: Aortic Aneurysm, Abdominal
Interventions: GORE® EXCLUDER® Conformable AAA Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 21 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more

Conditions: Esophageal Cancer
Interventions: conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy; Procedure · Radiation · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 35
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more

Conditions: Bacterial Vaginosis
Interventions: Metronidazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more

Conditions: Mycoses, Candidiasis, Invasive, Candidemia
Interventions: SCY-078, Fluconazole, Micafungin; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Burnout, Professional, Resilience, Psychological
Interventions: Three Good Things, Gratitude, Random Acts of Kindess, Awe, 1 Good Chat; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Palo Alto, California • Stanford, California • Boston, Massachusetts + 5 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 20 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 65
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Search by objective public record fields.

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Stress Management and Biomarkers of Risk in Cardiac Rehabilitation

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

A Registry for Patients Taking Uptravi

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Positron Emission Tomography in Determining Stage of Esophageal Cancer

Bacterial Vaginosis Home Screening to Prevent STDs

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Web-based Implementation for the Science of Enhancing Resilience Study

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)